Phase II Trial of Sorafenib in Metastatic Thyroid Cancer

PURPOSE: Based on the pivotal role of Ras-Raf-MAP-ERK signaling and vascular endothelial growth factor (VEGF) in papillary thyroid cancer (PTC), we conducted a phase II clinical trial of sorafenib targeting RAF and VEGF receptor kinases in PTC. PATIENTS AND METHODS: The primary end point was the obj...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kloos, Richard T., Ringel, Matthew D., Knopp, Michael V., Hall, Nathan C., King, Mark, Stevens, Robert, Liang, Jiachao, Wakely, Paul E., Vasko, Vasyl V., Saji, Motoyasu, Rittenberry, Jennifer, Wei, Lai, Arbogast, Daria, Collamore, Minden, Wright, John J., Grever, Michael, Shah, Manisha H.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2009
Materias:
Original Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2668972/
https://ncbi.nlm.nih.gov/pubmed/19255327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.18.2717
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares